EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSELUG00000018900
Gene Symbol: EGLN1
3 Cross references
208 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSELUG00000003505
Gene Symbol: EGLN3
3 Cross references
203 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 1

Ensembl ID : ENSELUG00000016998
Gene Symbol: EGLN1
3 Cross references
175 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSELUG00000012507
Gene Symbol: EPAS1
3 Cross references
213 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSELUG00000010010
Gene Symbol: ECE1
3 Cross references
231 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSELUG00000016244
Gene Symbol: EDNRB
3 Cross references
200 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSELUG00000005635
Gene Symbol: LOC105022329
3 Cross references
156 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSELUG00000014189
Gene Symbol: LOC105020933
3 Cross references
205 Possible Orthologues:

Endothelin-1 Receptor

Ensembl ID : ENSELUG00000006885
Gene Symbol: LOC105008632
3 Cross references
201 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSELUG00000010686
Gene Symbol: EZH2
3 Cross references
240 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSELUG00000024112
Gene Symbol: LOC105019998
3 Cross references
212 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSELUG00000017562
Gene Symbol: EGFR
3 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).